Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus.
More than 90% of cats immunized with inactivated whole infected-cell or cell-free feline immunodeficiency virus (FIV) vaccines were protected against intraperitoneal infection with 10 50% animal infectious doses of either homologous FIV Petaluma (28 of 30 cats) or heterologous FIV Dixon strain (27 of 28 cats). All 15 control cats were readily infected with either strain of FIV. Protection appears to correlate with antiviral envelope antibody levels by a mechanism yet to be determined.
Department of Medicine, School of Veterinary Medicine, University of California, Davis 95616.
J K
JK
Yamamoto
T
T
Hohdatsu
R A
RA
Olmsted
R
R
Pu
H
H
Louie
H A
HA
Zochlinski
V
V
Acevedo
H M
HM
Johnson
G A
GA
Soulds
M B
MB
Gardner
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002415:Cats; D016089:Immunodeficiency Virus, Feline / Q000276:immunology* / Q000302:isolation & purification; D016180:Lentivirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000662:veterinary*; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000627:therapeutic use*; D014759:Viral Envelope Proteins / Q000276:immunology
D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014759:Viral Envelope Proteins